文献速递心脑血管急症重症综合管理与镇静镇痛

AAV9.LAMP2B基因治疗Danon病的1期研究

Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease.
PubMed 文献 · N Engl J Med · 2024-11-18
一句话结论单次输注RP-A501在7例男性Danon病患者中似乎安全,6例左室射血分数正常者出现心脏LAMP2表达及临床改善,随访24至54个月。

Danon病是LAMP2基因突变所致的罕见X连锁单基因心肌病,男性患者表现为进行性心脏肥厚、心功能障碍和早死,目前无针对性治疗。这项1期研究评估单次输注RP-A501(含LAMP2B转基因的AAV9载体)的安全性及疗效。7例男性患者接受输注,均接受泼尼松、他克莫司或西罗莫司及利妥昔单抗的短暂免疫调节方案。1例发生补体介导的血栓性微血管病(4级)伴血小板减少和急性肾损伤,3例出现糖皮质激素相关Danon病骨骼肌病加重(3级),1例基线左室收缩功能障碍者进展为心力衰竭并在输注后5个月接受移植。6例基线左室射血分数正常者出现心脏LAMP2蛋白表达、左室质量指数较基线降低或稳定、左室射血分数保持、心肌肌钙蛋白I和N末端B型利钠肽原水平降低或稳定。24至54个月时全部患者存活,副作用完全消退。

要点

  • 7例男性Danon病患者接受单次RP-A501输注,其中5例≥15岁,2例11至14岁,均接受泼尼松、他克莫司或西罗莫司及利妥昔单抗的短暂免疫调节方案。
  • 1例发生补体介导的血栓性微血管病(4级)伴血小板减少和急性肾损伤,3例出现糖皮质激素相关Danon病骨骼肌病加重(3级)。
  • 1例基线左室收缩功能障碍者进展为心力衰竭,输注后5个月接受心脏移植。
  • 6例基线左室射血分数正常者出现心脏LAMP2蛋白表达、左室质量指数较基线降低或稳定、左室射血分数保持、心肌肌钙蛋白I和N末端B型利钠肽原水平降低或稳定。
  • 24至54个月时全部患者存活,副作用完全消退。

适用人群与场景

  • 男性Danon病患者,共7例,其中5例年龄15岁或以上,2例年龄在11至14岁之间。

处置流程与药物剂量

  • 单次输注RP-A501(含LAMP2B转基因的重组腺相关病毒血清型9)。
  • 所有患者接受泼尼松、他克莫司或西罗莫司及利妥昔单抗的短暂免疫调节方案。

红旗征与不能漏的情况

  • 补体介导的血栓性微血管病(4级)伴血小板减少和急性肾损伤。
  • 糖皮质激素相关Danon病骨骼肌病加重(3级)。
  • 基线左室收缩功能障碍患者出现进行性心力衰竭,需心脏移植。

研究设计与关键结果

  • 1期研究纳入7例男性Danon病患者,单次输注RP-A501,主要结局为安全性和毒性、心肌LAMP2转导和蛋白表达、心力衰竭症状稳定或减轻、心脏结构和功能稳定或改善。
  • 1例发生补体介导的血栓性微血管病(4级)伴血小板减少和急性肾损伤;3例发生糖皮质激素相关Danon病骨骼肌病加重(3级);1例基线左室收缩功能障碍者输注后5个月因进行性心力衰竭接受移植。
  • 6例基线左室射血分数正常者出现心脏LAMP2蛋白表达,左室质量指数较基线降低或稳定,左室射血分数保持,心肌肌钙蛋白I和N末端B型利钠肽原水平降低或稳定。
  • 24至54个月随访时全部患者存活,副作用完全消退。

证据类型、等级与局限

  • 证据类型:1期研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,单次RP-A501输注似乎安全,并与心脏LAMP2表达及24至54个月期间的临床改善证据相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predominant phenotype is progressive cardiac hypertrophy, cardiac dysfunction, and early death. There are no directed therapies for the disease.

METHODS: In this phase 1 study, we evaluated the safety and efficacy of a single infusion of RP-A501, a recombinant adeno-associated virus serotype 9 containing the transgene LAMP2B, which encodes an isoform of LAMP2. The primary outcomes were the safety and toxic effects of RP-A501, myocardial LAMP2 transduction and protein expression, stabilization of or reduction in heart-failure symptoms, and stabilization of or improvement in cardiac structure and function. Key secondary outcomes were sustained reduction in or stabilization of symptoms, immunologic response to RP-A501, end-stage heart failure, and overall survival. Exploratory outcomes included improvement in serologic markers of cardiac disease, patient-reported outcomes, and quality-of-life assessments.

RESULTS: RP-A501 infusion was administered to seven male patients with Danon disease: five who were 15 years of age or older and two who were between 11 and 14 years of age. All the patients received a transient immunomodulatory regimen of prednisone, tacrolimus or sirolimus, and rituximab. Phase 1 data over 24 to 54 months, including interim data from a long-term follow-up study, are reported here. One patient had complement-mediated thrombotic microangiopathy (grade 4) with thrombocytopenia and acute kidney injury. Three patients had glucocorticoid-related exacerbation (grade 3) of Danon disease-related skeletal myopathy. One patient with left ventricular systolic dysfunction at baseline had progressive heart failure and underwent transplantation 5 months after infusion. In the six patients with normal left ventricular ejection fraction at baseline, we observed cardiac LAMP2 protein expression and a reduction from baseline in or stabilization of the left ventricular mass index, preservation of left ventricular ejection fraction, and reduction in or stabilization of the levels of cardiac troponin I and N-terminal pro-B-type natriuretic peptide. At 24 to 54 months, all the patients were alive, with complete resolution of side effects.

CONCLUSIONS: A single infusion of RP-A501 appeared to be safe and was associated with cardiac LAMP2 expression and evidence of clinical improvement over a period of 24 to 54 months. (Funded by Rocket Pharmaceuticals; ClinicalTrials.gov number, NCT03882437.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Greenberg B, Taylor M, Adler E, et al. Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. 2024. PMID: 39556016. doi:10.1056/NEJMoa2412392

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。